Form 4: NEXGEL Director Steven Glassman Granted Stock Options and Restricted Stock Units

NEXGEL, Inc. Director Steven Mark Glassman was granted 30,000 stock options and 5,000 restricted stock units (RSUs) on June 25, 2025, as compensation for his service on the Board of Directors.

Summary

• Steven Mark Glassman, a Director of NEXGEL, INC. (NXGL), was granted 30,000 stock options and 5,000 restricted stock units (RSUs) on June 25, 2025.
• The stock options have an exercise price of $2.32 per share and expire on June 25, 2035.
• Both the stock options and RSUs were granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended.
• The 30,000 stock options will vest in equal 2,500 share amounts monthly over 12 continuous months, beginning July 31, 2025.
• The 5,000 restricted stock units will vest in equal 417 share amounts monthly over 12 continuous months, beginning July 31, 2025 (with 413 shares vesting in the twelfth month due to rounding).
• Vesting for both grants is subject to Mr. Glassman's continuous service through each vesting date.
• In the event of a Change in Control, any unvested shares underlying both the stock option and RSU grants will accelerate in accordance with the Plan's terms.
• These grants are for services as a member of the Issuer's Board of Directors and, for the RSUs, as Chairperson of the Board, until the Issuer's 2026 Annual Meeting of Stockholders.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as it represents a standard equity grant to a director, aligning their interests with shareholders and serving as a retention mechanism. There are no negative financial implications beyond minor, expected dilution.

Positives

• The grants align the interests of Director Steven Mark Glassman with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and retention of key board members.
• The grants are part of a pre-existing, approved incentive plan (2019 Long-Term Incentive Plan), indicating a structured approach to executive compensation.

Negatives

• The issuance of new stock options and restricted stock units, upon vesting and exercise, will result in a minor dilution of existing shareholder equity.

Risks

• The vesting of the stock options and RSUs is contingent upon Mr. Glassman's continuous service, meaning he would forfeit unvested portions if his service terminates.
• The value of the stock options is dependent on the future market price of NEXGEL's common stock exceeding the exercise price of $2.32.
• A Change in Control event could accelerate vesting, potentially leading to a large number of shares entering the market at once, though this is also a benefit to the recipient.

Future Outlook

The grants include forward-looking vesting schedules for both stock options and restricted stock units, commencing July 31, 2025, and continuing monthly for 12 months. The stock options have an expiration date of June 25, 2035, indicating a long-term incentive horizon. The grants are tied to service through the 2026 Annual Meeting of Stockholders.

Industry Context

This Form 4 filing details a standard equity compensation grant to a director, a common practice across industries to align management and board interests with shareholder value. It does not provide information on broader industry trends or competitive positioning.

Related Party Transactions

• The grants of stock options and restricted stock units to Steven Mark Glassman, a Director of NEXGEL, constitute a related party transaction as part of his compensation for board service.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting and exercise of the equity awards, but improved alignment of director interests with long-term shareholder value.
• Employees: No direct impact mentioned, but the existence of an incentive plan may signal a broader compensation philosophy.

Next Steps

• Monthly vesting of stock options and restricted stock units will commence on July 31, 2025, and continue for 12 months.
• Steven Mark Glassman's service as a Director and Chairperson of the Board is expected to continue until the Issuer's 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

NEXGEL, NXGL, SEC Form 4, Insider Transaction, Stock Option Grant, Restricted Stock Units, RSU, Director Compensation, Equity Incentive Plan, Vesting Schedule, Corporate Governance